Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06074016
PHASE1

Pharmacokinetics in Oral and Intranasal Formulations of Zolmitriptan.

Sponsor: Parc de Salut Mar

View on ClinicalTrials.gov

Summary

This is a phase I study to evaluate the PBPK of zolmitriptan intranasal versus oral administration.

Official title: Pharmacokinetic Model Based on Population Physiology of Oral and Intranasal Formulations of Zolmitriptan in Healthy Volunteers

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

8

Start Date

2023-07-12

Completion Date

2023-09-29

Last Updated

2026-05-05

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Zolmitriptan intranasal.

Zolmitriptan nasal spray is supplied in a single-use, ready-to-use spray unit. It is administered in one nostril. The full protocol will explain how to use it. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.

DRUG

Zolmitriptan oral.

Zolmitriptan 5 mg orally disintegrating tablet is to be taken without liquids. For oral administration, each tablet will be placed in the top of the tongue without any liquid and will disperse in a matter of seconds, then be swallowed with saliva. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.

Locations (1)

IMIM (Hospital del Mar Medical Research Institute)

Barcelona, Spain